Poster Presentations

Lymphoma biology
Abstract Book Number Category Title Presenter
168 Lymphoma biology C5ORF30/ MACIR is a robust prognostic marker in DLBCL, and modulates the tumor microenvironment through HLA expression Zi Yan Charmaine  Ong
169 Lymphoma biology Phospho-STAT3 Expression and JAK/STAT Pathway Activation across Genetic Subtypes of Diffuse Large B-Cell Lymphoma Aitana Avendaño Pomares
170 Lymphoma biology Role of Non-Coding RNAs and DNA Methylation in Regulating Intracellular Signaling and Cytokine Pathways in MYD88WT  Waldenström Macroglobulinemia: A Multi-Omic Analysis Karan L Chohan
171 Lymphoma biology Stabilized MYCT58A Bypasses T-Cell Help to Fuel Germinal Center B-Cell Lymphomagenesis Baizhi  Chen
172 Lymphoma biology Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark Zone Claudio  Tripodo
173 Lymphoma biology FLI1 Interactome in Diffuse Large B-Cell Lymphoma Identifies ATG9A as a Novel Autophagy-Related Interactor Giulio  Sartori
174 Lymphoma biology Phosphoinositide dependent protein kinase 1 is a key metabolic regulator and potential therapeutic target in lymphoma. Ondrej  Havranek
175 Lymphoma biology Cyclin D1 Overexpression Induces Replication Stress and Microhomology-Mediated
End-Joining Dependence for DNA Damage Repair in Mantle Cell Lymphoma 
Jithma  Abeykoon
Lymphoma genetics
Abstract Book Number Category Title Presenter
176 Lymphoma genetics EGR2 mutations Confer Poor Prognosis in Chronic Lymphocytic Leukemia Treated with Bruton Tyrosine Kinase Inhibitors Huayuan  Zhu
177 Lymphoma genetics Genetic Profiling of Marginal Zone Lymphoma in ctDNA at Diagnosis and During Follow-up: Diagnostic and Prognostic Implications Ramón  Diez-Feijóo
178 Lymphoma genetics Clinical characteristics and molecular heterogeneity in Follicular Lymphoma with extranodal involvement  Weili  Zhao
179 Lymphoma genetics Genomic and transcriptional single-cell heterogeneity in germinal-center (GC) lymphomas: insights into follicular lymphoma transformation Sofía  Huerga-Domínguez
180 Lymphoma genetics Impact of TP53 mutations and copy number loss on survival outcomes for patients with newly diagnosed large B cell lymphomas Daniel J Landsburg
181 Lymphoma genetics MYC rearrangements in large B-cell lymphomas: impact of the breakpoint and partner on prognosis Mariana  Bastos-Oreiro
182 Lymphoma genetics Genomic testing in patients with large cell and follicular lymphoma treated with T-cell engagers bi-specific antibodies and correlation with treatment response Rita  Tavarozzi
183 Lymphoma genetics Mutational Landscape of B-Cell Lymphomas: Clinical Evaluation of the MSK-ACCESS Heme cell-free DNA Next-Generation Sequencing Assay  Alfredo  Rivas-Delgado
184 Lymphoma genetics Genomic profiling of extranodal (EN) disease in patients (pts) with diffuse large B-cell lymphoma(DLBCL): A combined analysis of POLARIX and GOYA Jennifer K. Lue
185 Lymphoma genetics Comprehensive analysis identifies distinct patterns of molecular alterations across age groups in diffuse large B-cell lymphoma Manik  Uppal
186 Lymphoma genetics An In Vivo PiggyBac Insertional Mutagenesis Screen To Search for Modifiers of Myd88L265P-driven DLBCL Lymphomagenesis Svenja  Höfmann
187 Lymphoma genetics Mutational BCL10 Activation Cooperates with BCL6 in DLBCL Lymphomagenesis Facilitating Subtype-Specific Precision In Vivo Modeling Jonathan  H Schatz
188 Lymphoma genetics Influence of TP53 gene alterations in patients with Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL) treated with Bispecific Antibodies (BsAbs) Marc  Bosch Schips
189 Lymphoma genetics  Therapy-Driven Evolution and Intratumoral Genetic Heterogeneity in CNS Lymphomas  James Louis Rubenstein
190 Lymphoma genetics Oncogenesis of Enteropathy-Associated T-cell lymphoma: extensive parallel clonal evolution and its clinical consequences Bauke  Ylstra
Lymphoma classification
Abstract Book Number Category Title Presenter
191 Lymphoma classification  InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO 5th Edition classification (2024) Alyssa I Clay-Gilmour
192 Lymphoma classification  Follicular lymphoma displays distinct gene expression profiles according to histological grade Allison  Barraclough
193 Lymphoma classification  Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell-of-origin and patient outcomes Weicheng  Ren
194 Lymphoma classification  A novel approach for classification of splenic B cell lymphoma using DNA methylation reveals diverse biological disease mechanisms Christopher  Oakes
195 Lymphoma classification  Multi-omics dissection of EBV-driven heterogeneity, metabolic remodeling, and tumor cellular landscape in ENKTL progression Jinhua  Liang
196 Lymphoma classification  DNA Methylation Signatures Distinguish Extranodal NK/T-cell Lymphoma (ENKTL) and EBV-Positive Nodal T/NK-Cell Lymphoma (nTNKL) and Identify Prognostic Subgroups  The  Phyu
Lymphoma microenvironment
Abstract Book Number Category Title Presenter
197 Lymphoma microenvironment  CD4+ T cell recruitment and differentiation into a cytotoxic phenotype is associated with the treatment of patients with glofitamab together with R-CHOP or Pola-R-CHP Thiago M.  Steiner
198 Lymphoma microenvironment  CD3xCD20 bispecific epcoritamab induces antitumor activity and favorable T-cell dynamics over time with prolonged therapy Edith  Szafer-Glusman
199 Lymphoma microenvironment  Pembrolizumab therapy induces an inflammatory response in lymphoma patients by reshaping monocytes resulting in hyperprogressive disease Zhi-Zhang  Yang
200 Lymphoma microenvironment  Spatial Transcriptomics Reveals Immune Microenvironment Remodeling in Cutaneous T-Cell Lymphoma Post-Radiation and Biomarkers of Disease Progression Alan  Zhou
201 Lymphoma microenvironment  Gut microbiome-derived short-chain fatty acid sodium butyrate shape the immune response in chronic lymphocytic leukemia Monika  Szelest
202 Lymphoma microenvironment  Immunosurveillance of Precancerous Germinal Center B Cells  LINGLING  ZHANG
203 Lymphoma microenvironment  Characterization and clinical impact of the circulating immune cell profile in patients with follicular lymphoma (FL)  Andrea  Rivero
204 Lymphoma microenvironment  An explainable artificial intelligence mDELRelapseNet model to predict relapse in Diffuse Large B-Cell Lymphoma based on the Spatial Organization of MYC+BCL2+BCL6- Cells Shruti   Sridhar
205 Lymphoma microenvironment  Investigating Neutrophil Extracellular Traps as a possible prognostic marker in diffuse large B-cell lymphoma and classical Hodgkin lymphoma Emma  Pettersson
206 Lymphoma microenvironment  Spatial and Single-Cell Multi-omics Reveal Macrophage Heterogeneity between Primary CNS Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL) Liang  Hong
207 Lymphoma microenvironment  Association between Nodular lymphocyte-predominant Hodgkin Lymphoma and Moraxella catarrhalis  Izidore S. Lossos
Chronic lymphocytic leukemia
Abstract Book Number Category Title Presenter
208 Chronic lymphocytic leukemia  Comparative efficacy of ibrutinib vs other covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia: A matched-adjusted indirect comparison Alexey  Danilov
209 Chronic lymphocytic leukemia  Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive CLL: a matching-adjusted indirect comparison Talha  Munir
210 Chronic lymphocytic leukemia  Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia Ryan  Jacobs
211 Chronic lymphocytic leukemia  Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (ReVenG) in patients with recurrent CLL Matthew S. Davids
212 Chronic lymphocytic leukemia  SAVE (Safe Accelerated Venetoclax Escalation): Results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL Jennifer L. Crombie
213 Chronic lymphocytic leukemia  Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL: results in SEQUOIA arm D Mazyar  Shadman
214 Chronic lymphocytic leukemia  Final Independent Review Data Supports Sustained Benefit of Zanubrutinib over Ibrutinib in Patients with R/R CLL/SLL in ALPINE Jennifer R.  Brown
215 Chronic lymphocytic leukemia  Discontinuation of BTK Inhibitor Monotherapy in CLL Patients Without Disease Progression: A Real-World (RW) Study from the Spanish CLL Group (GELLC) Ana Carla  De Oliveira
216 Chronic lymphocytic leukemia  EPCORITAMAB MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE CLL-1 Bita  Fakhri
217 Chronic lymphocytic leukemia  Richter's transformed chronic lymphocytic leukemia of diffuse large B-cell lymphoma (DLBCL) - type compared to de novo DLBCL in a nationwide cohort  Andreas  Katsimigas
218 Chronic lymphocytic leukemia  Analysis of COVID-19 Infections With Fixed-Duration Acalabrutinib-Venetoclax Combinations in Treatment-Naive Chronic Lymphocytic Leukemia in the Phase 3 AMPLIFY Trial John F. Seymour
219 Chronic lymphocytic leukemia  Patient reported outcomes from BRUIN CLL-321: Phase 3 trial comparing pirtobrutinib to idelalisib/rituximab or bendamustine/rituximab in covalent BTKi pretreated CLL/SLL Paul   Barr
220 Chronic lymphocytic leukemia  HIGH EFFICACY OF BRIEF BRAF AND MEK COINHIBITION, ALONE AND COMBINED WITH ANTI-CD20 IMMUNOTHERAPY, IN RELAPSED/REFRACTORY (R/R) HAIRY CELL LEUKEMIA (HCL): A PHASE-2 TRIAL Enrico  Tiacci
Follicular Lymphoma
Abstract Book Number Category Title Presenter
221 Follicular Lymphoma  Determining the prognostic significance of the Ki67 proliferation index in treatment-naïve follicular lymphoma: An Australasian Lymphoma Registry (LaRDR) study Eliza A Hawkes
222 Follicular Lymphoma  Exploration of surrogate markers for EZH2 Y646 mutation in follicular lymphoma: comparative study including matched pair samples Kennosuke  Karube
223 Follicular Lymphoma  Prognostic Role of interim ΔSUVmax in Follicular Lymphoma Rexhep  Durmo
224 Follicular Lymphoma  Regular Aspirin Use Prior to Diagnosis and Follicular Lymphoma Prognosis: Novel Association with Superior Event-Free Survival George  Cholack
225 Follicular Lymphoma  The FOREST Study: A Prospective Observational Study on Real-World Management and Outcomes of Follicular Lymphoma in Japan Wataru  Munakata
226 Follicular Lymphoma  Follicular Lymphoma Transformation: Real-World Analysis including effect of rituximab/obinutuzumab Dor  Shpitzer
227 Follicular Lymphoma  Rituximab and Epcoritamab as First-line Therapy for Patients with High-tumor Burden Follicular Lymphoma: First Results of a Multicenter Phase II Trial Reid  Merryman
228 Follicular Lymphoma  A UC Hematologic Malignancy Consortium Phase II Trial of Obinutuzumab, Ibrutinib and Venetoclax in Patients with Previously Untreated Follicular Lymphoma Aneeqa   Zafar
229 Follicular Lymphoma  Safety and efficacy of mosunetuzumab subcutaneous maintenance following mosunetuzumab plus lenalidomide induction therapy in previously untreated follicular lymphoma Toby A. Eyre
230 Follicular Lymphoma  Treatment Of newly-diagnosed Follicular Lymphoma with Rituximab, Golcadomide +/- Nivolumab- Interim analysis of the Phase II TOP-FLOR study Eliza  A Hawkes
231 Follicular Lymphoma  Impact of Rituximab Early Administration on Outcomes in Advanced Stage Low Tumor Burden Follicular Lymphoma: Subgroup Analysis of Phase III JCOG1411/FLORA Study Dai  Maruyama
232 Follicular Lymphoma  Combination of the Intravenous PI3K Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with Previously Untreated Follicular Lymphoma and High Tumor Burden Christian Christian Schmidt
233 Follicular Lymphoma  S1608: Randomized phase II trial comparing lenalidomide/obinutuzumab and umbralisib/obinutuzumab with chemoimmunotherapy in early progressing follicular lymphoma (POD24) Paul M Barr
234 Follicular Lymphoma  Post Hoc Analysis of Outcomes by POD24 Status From the inMIND Study of Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma Laurie H. Sehn
235 Follicular Lymphoma  Nemtabrutinib in Relapsed or Refractory Follicular Lymphoma: Updated Results From Cohort G of the Phase 2 BELLWAVE-003 Study Wojciech  Jurczak
236 Follicular Lymphoma  Mosunetuzumab (Mosun) demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL) Chan Y. Cheah
237 Follicular Lymphoma  Fixed-duration subcutaneous mosunetuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with high-risk features: pivotal Phase II study update Laurie H. Sehn
238 Follicular Lymphoma  Epcoritamab Plus Lenalidomide and Rituximab Achieves High Response Rates and Survival Benefits Compared With Usual Care in Relapsed/Refractory Follicular Lymphoma Lorenzo  Falchi
239 Follicular Lymphoma  Machine Learning Based Unsupervised Multimodal Analysis Identifies Patient Subsets Associated with Response to Mosunetuzumab in Relapsed/Refractory NHL Habib  Hamidi
240 Follicular Lymphoma  EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3-YEAR FOLLOW-UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA Kim M. Linton
241 Follicular Lymphoma  Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide vs Tafasitamab With Rituximab + Lenalidomide in Second-Line + Follicular Lymphoma Julie M Vose
242 Follicular Lymphoma  Long-term efficacy and survival outcomes with odronextamab in relapsed/refractory follicular lymphoma (R/R FL): 2-year follow-up from the Phase 2 ELM-2 study  Stefano  Luminari
243 Follicular Lymphoma  Real-World Outcomes of CD20xCD3 Bispecific Antibody Therapy in Adult Patients with Relapsed/Refractory Transformed Indolent Lymphoma. Pierre  Stephan
244 Follicular Lymphoma  Tisagenlecleucel Versus Mosunetuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): A Matching-Adjusted Indirect Comparison (MAIC) Using 3-Year Follow-up Data Nathan H Fowler
245 Follicular Lymphoma  Efficacy and Tolerance of CAR T-cells in Patients with Relapsed or Refractory Follicular Lymphoma: Analysis from the French DESCAR-T Registry Loic  Ysebaert
246 Follicular Lymphoma  Comparative outcomes of lisocabtagene maraleucel (liso-cel) versus an external control arm (ECA) in third-line or later (3L+) R/R follicular lymphoma (FL) Loretta J.  Nastoupil
247 Follicular Lymphoma  Matching-adjusted indirect comparison of lisocabtagene maraleucel versus epcoritamab in patients with third-line or later relapsed or refractory follicular lymphoma Saurabh  Dahiya
248 Follicular Lymphoma  Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide vs Lisocabtagene Maraleucel in Second-Line Follicular Lymphoma J.C.   Villasboas
249 Follicular Lymphoma  FAST Score : A Machine Learning-Based Model Predicting Early Relapse after CAR T-cells in Follicular Lymphoma. Results from the French DESCAR-T Registry Yassine  Al Tabaa
250 Follicular Lymphoma  Histological Characteristics, Treatment Patterns, and Outcomes Following Disease Progression After CAR-T Therapy in Relapsed/Refractory Follicular Lymphoma  Alfredo  Rivas-Delgado
251 Follicular Lymphoma  High Complete Response Rates and Differential Toxicity of Mosunetuzumab and Lenalidomide in Previously Untreated Follicular (FL) and Marginal Zone Lymphoma (MZL) Adam J Olszewski
Marginal zone and lymphoplasmacytic lymphoma
Abstract Book Number Category Title Presenter
252 Marginal zone and lymphoplasmacytic lymphoma  IGHV and TP53 mutational status at diagnosis may have impact on outcome in patients with Splenic Marginal Zone Lymphoma Emilia  Cappello
253 Marginal zone and lymphoplasmacytic lymphoma  Nodal marginal zone lymphoma: mutational analysis, gene expression profile, and differential diagnosis from other small B-cell lymphomas. Leticia  Quintanilla-Martinez
254 Marginal zone and lymphoplasmacytic lymphoma  Rituximab and ibrutinib combination in untreated SMZL and NMZL: Long-term outcome and the impact of early minimal residual disease from the IELSG47/MALIBU Phase II Study  Catherine  Thieblemont
255 Marginal zone and lymphoplasmacytic lymphoma  The efficacy, safety and rationality of Orelabrutinib plus Obinutuzumab (O2) in systemic treatment-naïve marginal zone lymphoma: a prospective cohort study Jiadai  Xu
256 Marginal zone and lymphoplasmacytic lymphoma  Nemtabrutinib in Relapsed or Refractory Marginal Zone Lymphoma: Updated Results From Cohort F of the Phase 2 BELLWAVE-003 Study Alessandra  Tucci
257 Marginal zone and lymphoplasmacytic lymphoma  Zanubrutinib in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Efficacy and Safety of 101 Spanish Patients Treated in the Real-World on Behalf of GELTAMO Fernando  Martin-Moro
258 Marginal zone and lymphoplasmacytic lymphoma  A Meta-Analysis Investigating Response Rates of Continuous BTKi Monotherapies in the Treatment of B-Cell Lymphomas Pier Luigi  Zinzani
259 Marginal zone and lymphoplasmacytic lymphoma  IELSG49: A Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas Anastasios  Stathis
260 Marginal zone and lymphoplasmacytic lymphoma  Updated analysis of a phase 2 multicenter study of the loncastuximab in relapsed/refractory marginal zone lymphoma demonstrates high rate of complete responses Izidore S Lossos
261 Marginal zone and lymphoplasmacytic lymphoma  Survival is affected by comorbidity, age and sex - an observational study on 2988 Waldenstrom's macroglobulinemia patients in the Swedish Lymphoma Registry Eva   Kimby
262 Marginal zone and lymphoplasmacytic lymphoma  Free Light Chain (FLC) Ratio is an Independent Prognostic Risk Factor for Progression to Symptomatic Waldenstrom’s Macroglobulinemia Gianmarco  Favrin
263 Marginal zone and lymphoplasmacytic lymphoma  Long-term outcomes in  Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy Karan L Chohan
264 Marginal zone and lymphoplasmacytic lymphoma  CD3xCD20 bispecific antibodies in transformed  Waldenström macroglobulinemia/lymphoplasmacytic lymphoma Morgane  Brocard
Mantle Cell Lymphoma
Abstract Book Number Category Title Presenter
265 Mantle Cell Lymphoma  Impact of IGHV Repertoire after Ibrutinib-Containing Regimens in Younger untreated MCL Patients: An Analysis of the TRIANGLE Data Embedded in the MULTIPLY Project Simone  Ragaini
266 Mantle Cell Lymphoma  Integrative Analysis and identification of a predictive Epigenetic Signature in High-risk Mantle Cell Lymphoma: a LYSA study. Morgane  Cheminant
267 Mantle Cell Lymphoma  Evaluation of established prognostic markers in younger mantle cell lymphoma patients under ibrutinib containing regimens - An Analysis Embedded in the MULTIPLY Project Katja  Gutmair
268 Mantle Cell Lymphoma  The Effect of TP53 Mutations on the Local Response of Mantle Cell Lymphoma (MCL) to Radiation Therapy (RT)   Alok  Deshane
269 Mantle Cell Lymphoma  Real-world Treatment Patterns and Outcomes Among Patients With Treatment-Naive Mantle Cell Lymphoma in the UK, Sweden, and France Morgane   Cheminant
270 Mantle Cell Lymphoma  Real-world Treatment Patterns and Outcomes in High-Risk, Treatment-Naive Mantle Cell Lymphoma: A Multinational Analysis From the UK, Sweden, and France Alex   Smith
271 Mantle Cell Lymphoma  Leukemic non-nodal mantle cell lymphoma (nnMCL) is not necessarily equivalent to indolent MCL: A report from the LEO Cohort Study. Tony Zibo Zhuang
272 Mantle Cell Lymphoma  Acalabrutinib in combination with rituximab is highly effective frontline treatment for older patients with mantle cell lymphoma  Preetesh   Jain
273 Mantle Cell Lymphoma  Real-world outcomes of pirtobrutinib in relapsed/refractory mantle cell lymphoma: a multicenter analysis with a control cohort from the European MCL registry Enver  Aydilek
274 Mantle Cell Lymphoma  REAL WORLD ANALYSIS : USE OF BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED REFRACTORY MANTLE CELL LYMPHOMA OF ELDERLY PATIENTS (>70 years old) Vanderson  Rocha
275 Mantle Cell Lymphoma  Radiotherapy in Patients with Advanced Stage Mantle Cell Lymphoma achieves Durable Local Tumor Control– A SAKK/GLA/EMCL Real-World-Analysis from the EMCL-Registry Linda  Simon
276 Mantle Cell Lymphoma  Modern Trends and Outcomes of the Increasing Utilization of Radiation Therapy (RT) in Mantle Cell Lymphoma (MCL) Alok  Deshane
Aggressive B-cell lymphomas-first line clinical trials
Abstract Book Number Category Title Presenter
277 Aggressive B-cell lymphomas-first line clinical trials  Prephase Treatment with Vitamin D Supplementation in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): a Randomized Trial by Fondazione Italiana Linfomi (FIL) Tanja  Lazic
278 Aggressive B-cell lymphomas-first line clinical trials  Assessing the efficacy and toxicity of CNS prophylaxis in diffuse large B-cell lymphoma (CLSG-CNS-01): a randomized, multicenter, prospective phase 3 trial  Heidi  Mocikova
279 Aggressive B-cell lymphomas-first line clinical trials  Polatuzumab vedotin with dose adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (PERCH) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas Ryan C Lynch
280 Aggressive B-cell lymphomas-first line clinical trials  Glofitamab combined with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final results from the NP40126 study Max S. Topp
281 Aggressive B-cell lymphomas-first line clinical trials  LONG-TERM RESULTS FROM EPCORE NHL-2: FIXED-DURATION EPCORITAMAB + R-CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA WITH HIGH-RISK FEATURES Lorenzo  Falchi
282 Aggressive B-cell lymphomas-first line clinical trials  Durable Efficacy With Fixed-Duration Epcoritamab + Polatuzumab, Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) For 1L DLBCL (EPCORE NHL-5) Abraham  Avigdor
283 Aggressive B-cell lymphomas-first line clinical trials  A Ibrutinib and Standard Immunochemotherapy (R-CHOEP) In Younger, High-Risk Patients with DLBCL: a prospective, phase II study of German Lymphoma Alliance (GLA) Evgenii  Shumilov 
284 Aggressive B-cell lymphomas-first line clinical trials  Novel ZCR (Zanubrutinib, Chidamide, Rituximab) ± CHOP Regimen Demonstrates Promising Efficacy in Frontline Treatment of Double-Expressor Diffuse Large B-Cell Lymphoma Zhiming  Li
285 Aggressive B-cell lymphomas-first line clinical trials  Efficacy and Safety of Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) in Untreated Elderly and Frail DLBCL Patients: A Prospective Phase 2 Clinical Trial Yuhong  Ren
286 Aggressive B-cell lymphomas-first line clinical trials  The short-term dose-dense CARMEN program is associated with better tolerability and similar efficacy than other intensified regimens in high-grade B-cell lymphomas Federico  Erbella
287 Aggressive B-cell lymphomas-first line clinical trials  SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS (PTS) WITH BURKITT LYMHOMA Piera  Angelillo
Aggressive B-cell lymphomas outcomes
Abstract Book Number Category Title Presenter
288 Aggressive B-cell lymphomas outcomes  Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study Yuqin   Song
289 Aggressive B-cell lymphomas outcomes  Multicenter Real-World Outcomes of Frontline Pola-R-CHP in Treatment Naïve DLBCL Swetha Kambhampati Thiruvengadam
290 Aggressive B-cell lymphomas outcomes  Real-world safety and efficacy of Pola-R-CHP in patients with previously untreated DLBCL: analysis of 500 patients in the POLASTAR study Nobuhiko  Nakamura
291 Aggressive B-cell lymphomas outcomes  Match-Adjusted Comparison of Epcoritamab vs Non-Anthracycline Chemoimmunotherapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients With High Cardiovascular Risk Patrick Connor  Johnson
292 Aggressive B-cell lymphomas outcomes  Match-Adjusted Comparative Analysis of the Efficacy of Epcoritamab + R-miniCHOP vs R-miniCHOP in Previously Untreated Diffuse Large B-Cell Lymphoma Juraj   Ďuraš
293 Aggressive B-cell lymphomas outcomes  Is MYC-positive high-grade B-cell lymphoma with 11q aberration (HGBCL-11q,MYCR) a new subtype of lymphoma compared to classical MYC-negative HGBCL-11q?  Grzegorz  Rymkiewicz
294 Aggressive B-cell lymphomas outcomes  Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China Pengpeng  Xu
295 Aggressive B-cell lymphomas outcomes  Early mortality DLBCL prediction with an enhanced R-IPI (eR-IPI) score developed using an ensemble machine learning model. Paolo F. Caimi
296 Aggressive B-cell lymphomas outcomes  Limited stage diffuse large B cell lymphoma in the modern era: Real-world outcomes in an international study of over one thousand patients.  Allison  Barraclough
297 Aggressive B-cell lymphomas outcomes  Causes of excess non-lymphoma death in 60,000 patients with DLBCL diagnosed in England, 1997-2020: An observational cohort study with up to 25 years follow-up Andrew  Challenger
298 Aggressive B-cell lymphomas outcomes  The impact of socioeconomic Status on survival of patients with large B-cell lymphoma in Finland, a population-based analysis Joonas Benjamin Kuitunen
299 Aggressive B-cell lymphomas outcomes  Low socioeconomic status is associated with an inferior prognosis in diffuse large B-cell lymphoma patients despite the age Milla  Kuusisto-Jauhiainen
300 Aggressive B-cell lymphomas outcomes  Diffuse Large B-Cell Lymphoma in Brazil: A Comprehensive Analysis of Sociodemographic Patterns Guilherme  Duffles
301 Aggressive B-cell lymphomas outcomes  Socioeconomic disparities, disease burden and treatment intensity in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic cancer center Hua-Jay J Cherng
302 Aggressive B-cell lymphomas outcomes  Predicting outcomes in diffuse large B-cell lymphoma patients eligible for front-line trials using Harkins' enhanced eligibility criteria Jelena  Jeličić
303 Aggressive B-cell lymphomas outcomes  FERTILE: a long-term analysis of fertility among women treated with R-ACVBP/R-CHOP for diffuse large B-cell lymphoma, a retrospective, pooled study of LYSA trials Lucie  Oberic
304 Aggressive B-cell lymphomas outcomes  Imprint of cancer-induced immune scar remains for years and impairs adaptive immunity of NHL survivors Fabian  Müller
305 Aggressive B-cell lymphomas outcomes  RADIATION THERAPY ON SINGLE RESIDUAL PET POSITIVE LESIONS AFTER FRONTLINE CHEMIOIMMUNOTHERAPY IN DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER RETROSPECTIVE ANALYSIS Silvia  Ferrari
306 Aggressive B-cell lymphomas outcomes  Central Nervous System Relapse in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements: A Multicenter Study from the Spanish Group GELTAMO  Cristina  Garcia Herce
307 Aggressive B-cell lymphomas outcomes  Impact of Cell of Origin, Gene Rearrangements, Frontline Treatment on incidence of Central Nervous System (CNS) Lymphoma Relapse in Newly Diagnosed Large B-Cell Lymphoma  Ayo  S Falade
308 Aggressive B-cell lymphomas outcomes  Defining primary refractory disease in large B cell lymphoma and its association with outcomes: a secondary analysis of the LY.12 clinical trial Inna Y Gong
309 Aggressive B-cell lymphomas outcomes  Impact of Age on Treatment Decisions and Outcomes in Relapsed/Refractory Large B-Cell Lymphoma Massimiliano  Marinoni
310 Aggressive B-cell lymphomas outcomes  A Multi-center Real-life analysis on patients with Large B-cell Lymphoma after failure of CAR-T cells therapy. Mirko  Farina
311 Aggressive B-cell lymphomas outcomes  Outcomes of Patients with Primary Refractory and Early Relapsing Large B cell Lymphoma are Inferior in the CD19 CAR T cell therapy era Inna Y Gong
312 Aggressive B-cell lymphomas outcomes  Comparison of infectious complications in patients with relapsed/refractory non-Hodgkin lymphoma receiving CAR T cells vs. Bispecific Antibodies. Adaia  Albasanz-Puig
313 Aggressive B-cell lymphomas outcomes  Double Refractory Status Confirms Inferior Survival in Large B-cell Lymphoma Eligible for Third-line CD19 Chimeric Antigen T-cell Therapy Chathuri  Abeyakoon
314 Aggressive B-cell lymphomas outcomes  Isolated Central Nervous System (CNS) relapse after CAR-T cell infusion in large B-cell lymphomas (LBCL): an analysis from the Italian CART-SIE Study Annalisa  Chiappella
315 Aggressive B-cell lymphomas outcomes  Prognostic Impact of Extranodal Infiltration Based on Anatomic Locations at Plasmablastic Lymphoma Diagnosis in a Multicentric Spanish Series (GELTAMO)  Fernando  Martin-Moro
Relapsed/refractory aggressive B-cell lymphomas: clinical trials
Abstract Book Number Category Title Presenter
316 Relapsed/refractory aggressive B-cell lymphomas: clinical trials  Multi-targeted therapy with ViPOR-P in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Updated Analysis of Efficacy and Minimal Residual Disease (MRD) Christopher  Melani
317 Relapsed/refractory aggressive B-cell lymphomas: clinical trials  Molecular Subtype-Guided R-MINE+X Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single-arm, Open-label, Multicenter Phase II Study Jinhua  Liang
318 Relapsed/refractory aggressive B-cell lymphomas: clinical trials  Phase 2/3 waveLINE-003 Study: Zilovertamab Vedotin Plus Standard of Care in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Lalita  Norasetthada
319 Relapsed/refractory aggressive B-cell lymphomas: clinical trials  Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01) Won Seog   Kim
320 Relapsed/refractory aggressive B-cell lymphomas: clinical trials  Sustained remission with epcoritamab in relapsed/refractory large B-cell lymphoma (LBCL): EPCORE NHL-1 3-y results and analyses in patients with complete response at 2 y Chan Y Cheah
321 Relapsed/refractory aggressive B-cell lymphomas: clinical trials  Glofitamab, Poseltinib and Lenalidomide (GPL) for patients with relapsed/refractory diffuse large B cell lymphoma  Ja Min   Byun
322 Relapsed/refractory aggressive B-cell lymphomas: clinical trials  Epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2 Sven  de Vos
Relapsed/refractory aggressive B-cell lymphomas-real world
Abstract Book Number Category Title Presenter
323 Relapsed/refractory aggressive B-cell lymphomas-real world  A prospective analysis of the safety and efficacy of prophylactic dexamethasone for glofitamab administration in relapsed/refractory large B-cell lymphoma  J. Erika  Haydu
324 Relapsed/refractory aggressive B-cell lymphomas-real world  Rapid Ramp-up Dosing of Bi-specific Antibodies (BsAb) in Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL) Yucai  Wang
325 Relapsed/refractory aggressive B-cell lymphomas-real world  Match-Adjusted Comparative Analysis of Epcoritamab + R-DHAX/C or R-ICE vs R-DHAX/C or R-ICE in 2L+ Transplant-Eligible Patients With Diffuse Large B-Cell Lymphoma Justin  Darrah
326 Relapsed/refractory aggressive B-cell lymphomas-real world  Glofitamab and Epcoritamab for Large B Cell Lymphoma in 319 Real World Patients: A Retrospective U.K. Analysis of Efficacy, Tolerability and Practical Implications Euan  Haynes
327 Relapsed/refractory aggressive B-cell lymphomas-real world  Long-term outcome of patients with relapsed/refractory large B-cell lymphoma achieving CR using bispecific antibodies  Evgenii  Shumilov 
328 Relapsed/refractory aggressive B-cell lymphomas-real world  Intention-to-treatment analysis of third line CAR-T for relapse/refractory large B cell lymphoma Inna Y Gong
CNS Lymphomas
Abstract Book Number Category Title Presenter
329 CNS Lymphomas  Circulating protein biomarkers can aid differential diagnosis of primary CNS lymphomas and gliomas Mats  Hellström
330 CNS Lymphomas  Identification of genomic predictors of survival in primary central nervous system lymphomas.  Elisa  Aquilanti
331 CNS Lymphomas  Incidence and survival of primary CNS lymphoma: An England-wide cohort study from the UNCOVER Study Group Indrani  Karpha
332 CNS Lymphomas  A multi-center prospective phase II clinical trial of the MEDZ-R regimen for the treatment of newly diagnosed primary central nervous system lymphoma li  Zou
333 CNS Lymphomas  Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma Wenrong  Huang
334 CNS Lymphomas  A Phase I/II Study of Orelabrutinib Combined with Anti-PD-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL) Wanyue  Zhao
335 CNS Lymphomas  The impact of consolidation treatment after R-MVP induction chemotherapy in patients with primary diffuse large B-cell lymphoma of the CNS Jeong-Ok  Lee
336 CNS Lymphomas  CAR T-cell therapy is highly effective in vitreoretinal lymphomas. A LOC network study Sylvain  CHOQUET
337 CNS Lymphomas  Allogeneic Hematopoietic Stem Cell Transplantation for Primary Central Nervous System Lymphoma: An Analysis from the EBMT Lymphoma Working Party Igor  Age Kos
338 CNS Lymphomas  THREE-HOUR INFUSION OF METHOTREXATE AT 3 g/m2 SIGNIFICANTLY REDUCES CNS RELAPSES AND IMPROVES SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS AND INCREASED CNS RISK  Andrés J. M. Ferreri
339 CNS Lymphomas  Outcomes in an international multicentre study of 600 patients with CNS relapse of large B cell lymphoma: Compartment of relapse is prognostic Diva  Baggio
340 CNS Lymphomas  Prolonged Methotrexate, Temozolomide and Rituximab in Secondary Central Nervous System Lymphoma  Nikita K Dave
341 CNS Lymphomas  IBRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LARGE B-CELL LYMPHOMAS: EXPERIENCE FROM THE GELTAMO GROUP David  Alonso Castronuño
342 CNS Lymphomas  Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary CNS lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy Piera  Angelillo
343 CNS Lymphomas  A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) Caron  Jacobson
Primary mediastinal lymphoma
Abstract Book Number Category Title Presenter
344 Primary mediastinal lymphoma  RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) VERSUS RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TP  Vassilakopoulos
345 Primary mediastinal lymphoma  Primary mediastinal large B-cell lymphoma (PMBCL): a multicentric observational study of Spanish lymphoma group GELTAMO. Almudena  Cabero Martínez
346 Primary mediastinal lymphoma  RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) VERSUS RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TP  Vassilakopoulos
347 Primary mediastinal lymphoma  Anti-PD-1 antibody (Tislelizumab) combined with R-CHOP for the treatment of previously untreated primary mediastinal B-cell lymphoma: A prospective phase II study Wen  Shu juan
348 Primary mediastinal lymphoma  Long-term efficacy of immune checkpoint inhibitors for relapsed/refractory primary mediastinal B-cell lymphoma: a retrospective, monocentric study from Bologna, Italy. Vittorio  Stefoni
349 Primary mediastinal lymphoma  Pembrolizumab or nivolumab combined with brentuximab-vedotin in patients with relapsed/refractory primary mediastinal B-cell lymphoma: an Italian real-life study Alessandro  Broccoli
350 Primary mediastinal lymphoma  Patients with relapsed/refractory PMBCL have better survival when the salvage strategy includes CAR T-cells: an analysis of the REPRIME-FIL and the CART-SIE studies Anna  Guidetti
351 Primary mediastinal lymphoma  Final Safety Analysis in Participants With Hematologic Malignancies Who Received Allogeneic Stem Cell Transplant After Pembrolizumab Therapy John  Kuruvilla
Hodgkin Lymphoma
Abstract Book Number Category Title Presenter
352 Hodgkin Lymphoma  5-year Update on Frontline Brentuximab Vedotin with AVD for Stage II-IV HIV-associated Classical Hodgkin Lymphoma (AMC-085) Paul G. Rubinstein
353 Hodgkin Lymphoma  PET-Adapted Therapy After Three Cycles of ABVD for All Stages of Hodgkin Lymphoma: Long-Term Follow-Up of the GATLA LH-05 Trial Astrid   Pavlovsky
354 Hodgkin Lymphoma  A matching-adjusted indirect treatment comparison (MAIC) of BrECADD vs N+AVD in populations with advanced Hodgkin lymphoma (aHL) treated in the Front-Line (FL) Setting Alexa  Molinari
355 Hodgkin Lymphoma  Efficacy and Safety of the EVA Chemotherapy Regimen in Pregnant Patients with Hodgkin’s Lymphoma: A Long-Term Outcome Analysis Elżbieta   Wojciechowska-Lampka
356 Hodgkin Lymphoma  Metabolic Tumor Volume in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results from the GHSG HD21 Trial Justin  Ferdinandus
357 Hodgkin Lymphoma  A short (x3) nivolumab before BGD chemotherapy improves the remission rate in relapsed/refractory Hodgkin Lymphoma: N-BURGUND trial of the Polish Lymphoma Research Group. Jan Maciej Zaucha
358 Hodgkin Lymphoma  PD-1-based Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Real-World Analysis Hishan  Tharmaseelan
359 Hodgkin Lymphoma  Updated Results From KEYNOTE-B68: Pembrolizumab Every 6 Weeks in Participants with Relapsed or Refractory Classic Hodgkin Lymphoma or Primary Mediastinal B-cell Lymphoma Wojciech  Jurczak
360 Hodgkin Lymphoma  Bendamustine supercharge plus brentuximab vedotin as early salvage following failure of 2 ABVD cycles in HL: long-term results of a retrospective multicenter study  Claudia  Giordano
361 Hodgkin Lymphoma  Real-world outcomes of patient with relapsed or refractory Hodgkin lymphoma treated with Brentuximab-Vedotin in association with Bendamustine: the French LYSA experience  Krimo  Bouabdallah
362 Hodgkin Lymphoma  Brentuximab Vedotin-ICE as salvage treatment prior to stem cell transplant in Refractory and Relapsed Hodgkin Lymphoma Patients. A Multicenter Real-World Experience
 
Robin  NOEL
363 Hodgkin Lymphoma  Real-World Evidence of Brentuximab Vedotin Consolidation After Autologous Transplant in Relapsed/Refractory Hodgkin Lymphoma (rrHL): 2-Year Follow-Up from the GATLA Study Lorena  Fiad
364 Hodgkin Lymphoma  The role of stem cell transplantation in patients with R/R classical Hodgkin lymphoma treated with checkpoint inhibitors: Italian multicenter experience Elisa  Lucchini
365 Hodgkin Lymphoma  Association between anthracycline use and clinical outcomes in nearly 2,000 English patients aged 60-79 diagnosed with classical Hodgkin lymphoma between 2012 and 2020 Aisling  Barrett
366 Hodgkin Lymphoma  Evolving Treatment Landscape and Outcomes in Elderly Hodgkin Lymphoma: A 15-Year Multicenter Retrospective Analysis from China Highlighting the Impact of Novel Therapies Peiqi   Zhao
367 Hodgkin Lymphoma  AGE, FRAILTY, COMORBIDITIES AND FIRST-LINE TREATMENT IMPACT IN SURVIVAL OF ELDERLY HODGKIN LYMPHOMA PATIENTS: RETROSPECTIVE STUDY FROM THE SPANISH GELTAMO GROUP.  Eva  Domingo Domenech
368 Hodgkin Lymphoma  The Association of Social Disadvantage with Outcomes in Patients with Advanced-Stage, Classic Hodgkin Lymphoma (cHL) Enrolled in the Phase 3 Intergroup Trial S1826  Justine M Kahn
369 Hodgkin Lymphoma  Predicting Thrombotic Risk In Patients With Classical Hodgkin Lymphoma: Thro-HL Multicentre Study Ilaria  Del Giudice
370 Hodgkin Lymphoma  National Social Media Survey for Treatment Decision Making, Financial Toxicity, and Quality of Life in Adolescent and Young Adult Patients with Hodgkin Lymphoma Beatrice  Fregonese
371 Hodgkin Lymphoma  Synthetic control arm from clinical trial and real-world cohorts from LYSA group for untreated older classical Hodgkin lymphoma for innovative clinical trial designs Herve  Ghesquieres
Pediatric Lymphomas
Abstract Book Number Category Title Presenter
372 Pediatric lymphomas  Decoding the CD4+T cell- Hodgkin Reed-Sternberg cell crosstalk: how to cut the Achilles' heel of pediatric Hodgkin lymphoma? Diana  Petcu
373 Pediatric lymphomas  Prognostic value of 18F-FDG PET/CT volumetric parameters in childhood, adolescent, and young adult Hodgkin lymphoma: a systematic review from the SEARCH group. Sarah   Milgrom
374 Pediatric lymphomas  Imaging Pitfalls in Pediatric, Adolescent, and Young Adult Hodgkin Lymphoma: A SEARCH for CAYAHL Initiative to Bridge Multidisciplinary Patient Care Nawar  Dakhallah
375 Pediatric lymphomas  Real world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients in South China Jia  Zhu
376 Pediatric lymphomas  CD20-negative relapsed/refractory mature B-cell non-Hodgkin lymphoma (B-NHLs) and mature B-cell leukemia in children, adolescent andh young adults: a retrospective review Luciana  Vinti
377 Pediatric lymphomas  Late Complications and Quality of Life in Long-Term Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma Linnan  Wu
PTLD
Abstract Book Number Category Title Presenter
378 PTLD  Exploring a New Prognostic Index in 341 Post-Transplant Lymphoproliferative Disorders in the “Rituximab Era”: A Retrospective Study from Spanish Lymphoma Group GELTAMO  Ana  Jiménez-Ubieto
379 PTLD  Causes of death in post-transplant lymphoproliferative disorders: an analysis of the French K-VIROGREF registry Benjamin  Delarras
380 PTLD  First-line Therapy with Rituximab vs. Rituximab-CHOP in Post-Transplant Monomorphic Diffuse Large B-Cell Lymphoma: A Large Series from Spanish Group of Lymphoma (GELTAMO) Ana  Jiménez-Ubieto
381 PTLD  CD19 CAR-T cell therapy in relapsed/refractory solid organ transplant-related lymphoproliferation: A LYSA analysis of the French cohort DESCAR-T Emilie   Corvilain
NK/T-cell Lymphomas
Abstract Book Number Category Title Presenter
382 NK/T-cell Lymphomas  Gene copy number alterations identify subset of Sezary syndrome patients with worse survival outcomes. Francine Marie Ms  Foss
383 NK/T-cell Lymphomas  Next-Generation Sequencing Reveals T Cell Receptor Beta and Gamma Clonotypes Associated with Aggressive Subtypes of Mycosis Fungoides/Sezary Syndrome and Poor Prognosis Michelle   Afkhami
384 NK/T-cell Lymphomas  Prognostic and Functional Impact of EGF-JAK/STAT Pathway Mutations in Angioimmunoblastic T-cell Lymphoma (AITL) DACHUAN  HUANG
385 NK/T-cell Lymphomas  The prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma Yi Zhong
386 NK/T-cell Lymphomas  Number of extranodal sites in PTCL as prognostic marker in real-world setting. An analysis of 645 cases enrolled in the T-Cell Project 2. Thais   Fischer
387 NK/T-cell Lymphomas  Survival outcomes for patients with extra-nodal NK/T lymphoma; data from 110 patients prospectively registered in the International T-Cell Project 2 Christopher  Fox
388 NK/T-cell Lymphomas  Clinical Outcomes and Prognostic Factors in Nodal Aggressive T-Cell Lymphomas: Insights from 655 cases registered in the T-Cell Project 2.0 Stefano  Luminari
389 NK/T-cell Lymphomas  The outcome of Adult T-Cell Leukemia/Lymphoma in Real world setting: Insights from the T-Cell Project 2.0 Carlos S Chiattone
390 NK/T-cell Lymphomas  End-of-treatment PET/CT Complete Remission is Highly Prognostic in Nodal Peripheral T-cell Lymphoma: An Australasian-Canadian Collaborative Study  Chathuri  Abeyakoon
391 NK/T-cell Lymphomas  A phase II study of azacitidine and chidamide plus CHOP versus CHOP in previously untreated patients with peripheral T-cell lymphoma Chong  Wei
392 NK/T-cell Lymphomas  Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma Huimin  Liu
393 NK/T-cell Lymphomas  BV-CHP followed by autologous stem-cell transplantation in newly diagnosed Enteropathy-Associated T-cell lymphoma: Final results of the EATL-001 phase 2 study David  Sibon
394 NK/T-cell Lymphomas  Ruxolitinib targets STAT1-STAT3 cooperatively in large granular lymphocytic leukemia. Amira  Marouf
395 NK/T-cell Lymphomas  Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides in the Modern Era of TSEBT Dose Reduction and Diversified Systemic Therapy Kaitlyn  Lapen
396 NK/T-cell Lymphomas  Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Cutaneous T-Cell Lymphoma: Preliminary Results Julia  Scarisbrick
397 NK/T-cell Lymphomas  Robust Single Agent Activity of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter, in T Cell Lymphoma (TCL) Patients  Stefan  Barta
398 NK/T-cell Lymphomas  Lacutamab in patients with relapsed and/or refractory mycosis fungoides: long term follow-up and translational data from the TELLOMAK phase 2 trial Youn H  Kim
399 NK/T-cell Lymphomas  Durvalumab & Lenalidomide Shows Superior Efficacy Over Single-Agent Durvalumab in Refractory/Advanced Cutaneous T Cell Lymphoma: Results from a Randomized Phase 2 Trial Christiane  Querfeld
400 NK/T-cell Lymphomas  A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody Sintilimab in Combination With Pegaspargase and Anlotinib in Stage IV NKTCL Patients Rong  Tao
401 NK/T-cell Lymphomas  Phase II study of concurrent tislelizimab and radiotherapy for treatment-naïve, newly diagnosed low-risk Extranodal NK/T-cell lymphoma, nasal type  Won Seog  Kim
402 NK/T-cell Lymphomas  Relapsed/refractory Peripheral T-Cell Lymphomas: Report on 641 patients from the T-Cell Project 2.0.  Nazarii  Shokun
Multiple Myeloma
Abstract Book Number Category Title Presenter
403 Multiple Myeloma  A single-arm, multi-center, observational study of Selinexor combined bortezomib, lenalidomide, and dexamethasone in high-risk newly diagnosed multiple myeloma(NDMM)  Yuping  Zhong
404 Multiple Myeloma  Clinical relevance of Peripheral Blood Measurable Residual Disease(PBMRD) assessment in newly diagnosed Multiple Myeloma after Initial Therapy: A prospective study Gaurav  Chatterjee
405 Multiple Myeloma  Trends in the incorporation of radiotherapy in the management of Multiple Myeloma over the past decade: High local control rate and factors associated with its durability Alexandra D Dreyfuss
406 Multiple Myeloma  Combining Bispecifics and Radiation for Rel/Ref Hematologic Malignancies: Friend or Foe?  Hazim  Ababneh
407 Multiple Myeloma  Radiation Therapy for Oligo-Relapsed/Progressive Disease Post-Stem Cell Transplant for Multiple Myeloma: Factors Associated with Favorable Outcomes Beatrice  Fregonese
Imaging and radiomics
Abstract Book Number Category Title Presenter
408 Imaging and radiomics  Integrative Profiling of Gut Microbiome and FDG-PET Parameters as Predictors of CAR T-cell Therapy Outcomes in Relapsed/Refractory Diffuse Large B-cell Lymphomas. Beatrice  Casadei
409 Imaging and radiomics  Early Identification of CAR T-Cell Therapy Non-Responders in Relapsed/Refractory Large B-Cell Lymphoma Using FDG-PET Quantitative Parameters Cinzia  Pellegrini
410 Imaging and radiomics  Evaluation of an artificial intelligence method for lesion segmentation of baseline FDG PET studies of DLBCL patients  Maria C Ferrandez Ferrandez
411 Imaging and radiomics  The search for baseline imaging predictive factors of refractoriness to ABVD in the low and very low risk patients with early stages HL of the RAFTING trial Kateryna  Filonenko
412 Imaging and radiomics  Improving the predictive value of End-of-Treatment PET/CT in diffuse large B-cell lymphoma Anne  Bes
413 Imaging and radiomics  Progression patterns by positron emission tomography (PET) for relapsed/refractory Multiple Myeloma (RRMM) after CAR T cell therapy: Potential role for radiotherapy (RT)? Alexandra D Dreyfuss
414 Imaging and radiomics  CT-based body composition in patients with follicular lymphoma compared with the general population, and association between body composition and lymphoma outcomes Lea  Mantz
Liquid Biopsy
Abstract Book Number Category Title Presenter
415 Liquid Biopsy  Circulating Tumor DNA (ctDNA) at Screening as a Prognostic Marker in Untreated  Follicular Lymphoma from the GALLIUM Trail Using a Next Generation Sequencing (NGS) Assay Corinna  Lutterbeck
416 Liquid Biopsy  Real-life Disease Monitoring in Relapsed/Refractory Follicular Lymphoma Patients Using Liquid Biopsy Ultra-Deep Sequencing  Ana  Jiménez Ubieto
417 Liquid Biopsy  TMTV < than 32,5 ml impairs the successful detection of ctDNA in early-stage Hodgin lymphoma patients – the preliminary report from the RAFTING trial Marta Maria Bednarek
418 Liquid Biopsy  Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab Ryan C. Lynch
419 Liquid Biopsy  Multicenter Real-World Outcomes in Diffuse Large B-Cell Lymphoma Profiled with a Commercially-Available Circulating Tumor DNA Assay Patrick  Gould
420 Liquid Biopsy  Detection and Monitoring of response to treatment of B Cell Lymphomas By a Simple Epigenetic Blood Test Irit  Avivi
421 Liquid Biopsy  ctDNA Dynamics of Refractory Diffuse Large B Cell Lymphoma Ryan N Rys
422 Liquid Biopsy  Molecular features encoded in the dynamic ctDNA monitoring reveal prognostic value, different clinical courses and clone evolution for different genetic subtypes of DLBCL Jinhua  Liang
423 Liquid Biopsy  ctDNA-directed intervention with epcoritamab alone or in combination with lenalidomide-rituximab is feasible in the early post-CAR-T population at high risk of relapse Mark R. Dowling
424 Liquid Biopsy  Longitudinal targeted ctDNA analysis to assess CD20 and BAFF mutations in patients with relapsed/refractory FL or DLBCL progressing on odronextamab in the ELM-2 study  Stefano  Luminari
425 Liquid Biopsy  Biomarker analyses of the inflammatory profile and MRD in patients with relapsed/refractory marginal zone lymphoma versus follicular lymphoma treated with odronextamab Emmanuel  Bachy
426 Liquid Biopsy  EPCORITAMAB+GEMOX LEADS TO HIGH MRD-NEGATIVITY RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): AN UPDATED LONGITUDINAL MRD ANALYSIS Kubra  Karagoz
427 Liquid Biopsy  Monitoring Ciruclating Tumor DNA Improves Early Relapse Detection After Standard of care 2L+ Axi-cel in LBCL: A Prospective Study Snegha  Ananth
Experimental therapeutics
Abstract Book Number Category Title Presenter
428 Experimental therapeutics  The synthetic peptide CIGB-552 induces cell death and enhances ibrutinib efficacy in marginal zone lymphoma (MZL), including drug-resistant models Maidel  Carpio 
429 Experimental therapeutics  Loss of enhancer-derived lncRNA ZMIZ1-AS1 increases the sensitivity to BCL2-inhibitor venetoclax in MCL in vitro models Francesca  Guidetti
430 Experimental therapeutics  ARV-393, a PROTAC BCL6 degrader, combined with biologics or small-molecule inhibitors induces tumor regressions in diffuse large B-cell lymphoma models Anna   Van Acker
431 Experimental therapeutics  EZH2 gain-of-function mutations confer everolimus sensitivity in diffuse large B cell lymphoma Bryce W.Q. Tan
432 Experimental therapeutics  Loss of enhancer-derived lncRNA U47924.31 decreases R-CHOP sensitivity and is associated with inferior outcome in diffuse large B cell lymphoma (DLBCL) patients Nicolas  Munz
433 Experimental therapeutics  DEVELOPMENT OF HIGH-AFFINITY CD79B CAR-T CELLS TO OVERCOME ANTIGEN ESCAPE OF RELAPSED/REFRACTORY B-NON HODGKIN LYMPHOMAS AND MULTIPLE MYELOMA Vincenzo Maria Perriello
434 Experimental therapeutics  P-CD19CD20-ALLO1: A TSCM-Predominant Allogeneic CAR-T Therapy Targeting CD19 and CD20 for B-cell Malignancies Demonstrates Advantages Beyond Preventing Antigen Escape Samy  Jambon
435 Experimental therapeutics  Integrated Gene Expression and Pathway Enrichment Analyses Following CDK9 Inhibition in Cutaneous T-cell Lymphoma Patient-Derived Xenograft (PDX) Models  Weiyun  Ai
Novel compounds
Abstract Book Number Category Title Presenter
436 Novel compounds  Updated Efficacy/Safety of Bruton Tyrosine Kinase (BTK) Degrader BGB-16673 in Patients with Relapsed/Refractory (R/R) Indolent NHL: Ongoing Phase 1 CaDAnCe-101 Results Constantine S.  Tam
437 Novel compounds  Bexobrutideg (NX-5948), a novel BTK degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in  Waldenström macroglobulinemia David   Lewis
438 Novel compounds  Orelabrutinib for the treatment of relapsed/refractory mantle cell lymphoma: efficacy and safety results from a global phase 1/2 study Yucai   Wang
439 Novel compounds  Analysis of a Phase 1 Study of Zanubrutinib (Zanu) + Lenalidomide (Len) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Huilai  Zhang
440 Novel compounds  GoldiLox: First Experience of Two Dosing Strategies of Pirtobrutinib and Glofitamab for Mantle Cell Lymphoma Previously Treated with Covalent BTK Inhibitors Michael J Dickinson
441 Novel compounds  Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab, in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Phase 1/2 Results Raul  Cordoba
442 Novel compounds  Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma Raphael   Steiner
443 Novel compounds  A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed/Refractory Lymphoid Malignancies: Updated Analysis Wojciech  Jurczak
444 Novel compounds  A Phase 1 study of SGR-1505, an oral, potent MALT1 inhibitor for R/R B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Stephen  Spurgeon
445 Novel compounds  ELA026, a monoclonal antibody targeting SIRP-expressing myeloid cells and T lymphocytes, demonstrates broad anti-tumor activity in patients with lymphoma Swaminathan  Iyer
CAR T-cell therapy
Abstract Book Number Category Title Presenter
446 CAR T-cell therapy  Impact of Response to Holding/Bridging Therapy in Second-line DLBCL Patients Treated with Axicabtagene ciloleucel: a LYSA Study from the French DESCAR-T Registry Estelle  BOURBON
447 CAR T-cell therapy  POLATUZUMAB-CONTAINING REGIMENS AS BRIDGE TO CAR-T: INSIGHTS FROM THE ITALIAN CAR T-SIE STUDY Giulia  Gabrielli
448 CAR T-cell therapy  Bispecific antibodies as holding or bridging therapy before CAR-T in large B-cell lymphoma Hanna Katharina  Zieger
449 CAR T-cell therapy  Bridging to CAR-T cell therapy in large B-cell lymphoma with either conventional therapy or the CD3xCD20 bispecific antibody glofitamab Marie A-C. Neumann
450 CAR T-cell therapy  5-5-5 ABRT (Adaptive Bridging Radiation Therapy) – Artificial Intelligence Enters the CAR (-T) in Relapsed/Refractory Large B-Cell Lymphoma: Updated Analysis  Chirayu   Patel
451 CAR T-cell therapy  MYC Alterations Confer Worse Local Control In Patients Undergoing Bridging Radiotherapy Prior to CAR-T Roshal R.  Patel
452 CAR T-cell therapy  Bridging Radiotherapy Does Not Increase Risk of CAR T-cell Associated Toxicity Roshal R Patel
453 CAR T-cell therapy  Efficacy and Toxicity of Radiation Therapy Prior to Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma Kristin  Daniels
454 CAR T-cell therapy  Association of bridging therapy with response and outcomes in patients with relapsed/refractory large B cell lymphoma receiving third line CAR-T Inna  Gong
455 CAR T-cell therapy  Bendamustine as Lymphodepleting Chemotherapy (LDC) Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Alaa  Ali
456 CAR T-cell therapy  Identification of an Optimal Absolute Lymphocyte Count Before Leukapheresis in Large B-cell Lymphoma Patients Treated with CART Kunhwa  Kim
457 CAR T-cell therapy  Breath Biomarkers for Prediction of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-cell Therapy Teny M John
458 CAR T-cell therapy  Optimizing post–chimeric antigen receptor T cell monitoring: evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience Manali   Kamdar
459 CAR T-cell therapy  Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK Andrea  Kuhnl
460 CAR T-cell therapy  Circulating CAR T-cells after treatment with axicabtagene ciloleucel in patients with R/R aggressive B-cell lymphomas and its association to treatment outcome Louise  Olsson Werne
461 CAR T-cell therapy  Outcomes of CAR T-Cell Therapy in Transformed Indolent Non-Hodgkin Lymphomas and de novo DLBCL: a comparative analysis from the Italian CAR T-SIE study Nicole  Fabbri
462 CAR T-cell therapy  Outcomes After CAR-T cell Therapy (Tisagenlecleucel or Axicabtagene ciloleucel) in patients older than 70 years with  Diffuse Large B Cell Lymphoma  Vanderson   Rocha
463 CAR T-cell therapy  Anti-CD19 CAR-T Cell Therapy in Relapsed/Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma (THRLBCL): Insights from the French DESCAR-T Registry, a LYSA Study. Axel  André
New cellular therapies
Abstract Book Number Category Title Presenter
464 New cellular therapies  Durable responses and favourable toxicity after fast off-rate CD19 CAR T-cell therapy with obecabtagene autoleucel in adults with relapsed/refractory B-cell malignancies Claire  Roddie
465 New cellular therapies  Low Rates of High-Grade Toxicities With GLPG5101, a Fresh, Stem-Like, Early Memory Phenotype Anti-CD19 CAR T-Cell Therapy in Patients With NHL in the ATALANTA-1 Study Joost S.P. Vermaat
466 New cellular therapies  CAR-T Therapy with OX40 Signaling Drives Clonal Expansion of CD4+ T Cells and Overcomes Immunosuppressive Microenvironment in B-Cell Lymphoma: A Phase I Trial Ling-Shuang  Sheng
467 New cellular therapies  Safety and Efficacy of FT522, an Off-the-Shelf, iPSC ‑Derived CD19 CAR NK Cell Therapy with Alloimmune defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma Veronika  Bachanova
468 New cellular therapies  First-in-human CART cells for Adult T-Cell Leukemia/Lymphoma (ATLL) using CTX130, a CD70-Targeted Allogeneic CRISPR-Cas9-Engineered CART-Cells. COBALT-LYM Study Cohort.  R.Alejandro  Sica